Amyloid precursor protein (APP) RNAi agent compositions and methods of use thereof

US11034957B2 · kind B2 · utility

Assignee

• Alnylam Pharmaceuticals, Inc. · US

Inventors

• Stuart Milstein · Cambridge, US
• Kirk Brown · Swampscott, US
• Jayaprakash K. Nair · Cambridge, US
• Martin Maier · Cambridge, US
• Vasant Jadhav · Cambridge, US
• Mark Keating · Salt Lake City, US
• Adam Castoreno · Framingham, US
• Patrick Haslett · Cambridge, US
• Mangala Meenakshi Soundarapandian · Cambridge, US
• Kevin Fitzgerald · Brookline, US

Key dates

• Filing date: Jul 9, 2020
• Grant date: Jun 15, 2021
• Expiry date: Jul 9, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2750/14143
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting the APP gene, as well as methods of inhibiting expression of an APP gene and methods of treating subjects having an APP-associated disease or disorder, such as cerebral amyloid angiopathy (CAA) and early onset familial Alzheimer disease (EOFAD or eFAD), using such dsRNAi agents and compositions.